{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-288513","form_type":"8-K","ticker":null,"cik":"0001426332","company_name":"NGM BIOPHARMACEUTICALS INC","filed_at":"2023-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.035779+00:00","generated_at":"2026-06-07T18:40:30.555492+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NGM Biopharmaceuticals receives Nasdaq bid price deficiency notice; stock below $1.00 for 30 days","bullets":["Received Nasdaq notice on Dec 1, 2023; bid price below $1.00 for 30 consecutive business days.","Has until May 29, 2024 (180 days) to regain compliance by closing at $1.00+ for 10 consecutive days.","May transfer to Nasdaq Capital Market for an additional 180-day compliance period if needed.","Company will monitor and consider options, including a potential reverse stock split, to cure deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-288513","json":"https://secwatch.observer/filing/0001193125-23-288513.json","markdown":"https://secwatch.observer/filing/0001193125-23-288513.md","text":"https://secwatch.observer/filing/0001193125-23-288513.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426332/000119312523288513/0001193125-23-288513-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426332/000119312523288513/d618000d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T18:40:30.555492+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41ccc16f9335ec933aa1d5090780ffd41f859778","claim":"NGM BIOPHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"December 1, 2023, NGM Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1). The notification received has no immediate effect on the listing of the Company’s common stock on The Nasdaq Global Select Market. In","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1426332/000119312523288513/0001193125-23-288513-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}